Form 4: Cytokinetics Executive Fady Ibraham Malik Executes Stock Option and Sells Shares
SEC Form 4 Filing
EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, exercised stock options and sold a portion of the acquired shares on January 21, 2025.
Summary
- On January 21, 2025, Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc., exercised a non-qualified stock option to purchase 2,000 shares of common stock at a price of $10.60 per share.
- Simultaneously, Malik sold 2,000 shares of Cytokinetics common stock at a price of $45.92 per share.
- Following these transactions, Malik directly owns 116,071 shares of Cytokinetics common stock and 37,105 derivative securities.
Sentiment
Score: 5
Explanation: This is a routine Form 4 filing, reflecting standard insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking to understand management's perspective on the company's stock.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in ownership.
Key Dates
| Date | Description |
|---|---|
| 03/28/2017 | Date exercisable for Non-Qualified Stock Option |
| 02/28/2027 | Expiration date for Non-Qualified Stock Option |
| 01/21/2025 | Date of transaction: exercise of stock options and sale of shares. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.